ATROVENT SOLUTION

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

IPRATROPIUM BROMIDE

Disponible depuis:

BOEHRINGER INGELHEIM (CANADA) LTD LTEE

Code ATC:

R03BB01

DCI (Dénomination commune internationale):

IPRATROPIUM BROMIDE

Dosage:

250MCG

forme pharmaceutique:

SOLUTION

Composition:

IPRATROPIUM BROMIDE 250MCG

Mode d'administration:

INHALATION

Unités en paquet:

20ML

Type d'ordonnance:

Prescription

Domaine thérapeutique:

ANTIMUSCARINICS ANTISPASMODICS

Descriptif du produit:

Active ingredient group (AIG) number: 0115643001; AHFS:

Statut de autorisation:

CANCELLED POST MARKET

Date de l'autorisation:

2007-10-11

Résumé des caractéristiques du produit

_ _
_ _
_Page 1 of 33_
PRODUCT MONOGRAPH
Pr
Atrovent
®
(Ipratropium Bromide)
INHALATION SOLUTION
(20 mL bottle, 1 mL and 2 mL Unit Dose Vials)
BRONCHODILATOR
Boehringer Ingelheim (Canada) Ltd.
5180 South Service Road,
Burlington, Ontario
L7L 5H4
Date of Preparation:
September 19, 2003
Date of Revision:
May 16, 2006
Submission Control No:104456
BICL BPI # 0013-05, #0014-06, #0022-05
_ _
_ _
_Page 2 of 33_
Table of Contents
[To update, right-click anywhere in the Table of Contents and select
“Update Field”, “Update
entire table”, click OK.]
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................5
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND
ADMINISTRATION..............................................................................10
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND
STABILITY..........................................................................................13
SPECIAL HANDLING INSTRUCTIONS
.......................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
......................................................